BAYRY Stock Recent News

SAN DIEGO & BERLIN, Germany--(BUSINESS WIRE)--Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced it has secured exclusive worldwide rights to develop and commercialize the clinical-stage Werner helicase (WRN) covalent inhibitor VVD-214 (RO7589831), strengthening and complementing its innovative oncology development pipeline. VVD-214 was discovered and developed under an exclusi.

Airlines need to reach long-term agreements to buy bigger quantities of sustainable aviation fuel if they want to boost global volumes of the lower-emission fuel required for industry climate targets, a Bayer executive said on Tuesday.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that it will present multiple new analyses of the KERENDIA ® (finerenone) clinical trial program at the European Renal Association (ERA) 62nd Congress scientific sessions in Vienna, Austria, June 4-7, 2025. KERENDIA is currently approved to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), non-fatal myocardial infarction (MI), sustained eGFR decline, and end-stage kidney disease in adult patients with chronic.

Here is how Bayer Aktiengesellschaft (BAYRY) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.

BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data.

German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment Eylea, giving it a potential edge over Roche's rival treatment Vabysmo.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the launch of its Imaging Core Lab Services under the brand name Centafore. With over 25 years of experience supporting more than 200 clinical trials at Bayer and its arm's length companies globally, Centafore is now positioned as a distinct Imaging solution provider, offering tailored services for external customers to support their clinical trials and Software as a Medical Device (SaMD) development across diverse therapeutic areas and dev.

The phase I study evaluates BAYRY's investigational GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation.

WHIPPANY, N.J.--(BUSINESS WIRE)--The latest data from studies across Bayer's oncology and women's health portfolios will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from May 30–June 3. These data underscore Bayer's commitment to advancing treatments across different stages of cancer and driving the development of healthcare treatments, including for prostate and lung cancer. This year's ASCO presence also underscores Bay.

May is Women's Health Month – Dr. Yesmean Wahdan Shares Important and Timely Tips to Help Women Prioritize Their Health at Every Life Stage May is Women's Health Month – Dr. Yesmean Wahdan Shares Important and Timely Tips to Help Women Prioritize Their Health at Every Life Stage